U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07316972) titled 'CEST-based Biomarkers to Delineate the Epileptogenic Zone' on Dec. 19, 2025.
Brief Summary: Epilepsy is a common neurological disorder with an incidence of 1%. Although many anti-seizure medications are available, about 30% of patients are resistant to drug treatments. Epilepsy surgery is an effective treatment for some of these patients. It involves removing the brain region responsible for generating seizures, called the epileptogenic zone (EZ).
A pre-surgical evaluation is performed to locate and delineate the region where seizures originate (the seizure onset zone [SOZ]) and to confirm that this zone is unique and accessible for...